跳至主要内容
临床试验/NL-OMON44667
NL-OMON44667已完成3 期

An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis (CAIN457F2305E1) - CAIN457F2305E1

ovartis0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
ovartis
入组人数
9

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Subjects must have completed the core study
  • Subjects who are deemed by the investigator to benefit from continued secukinumab therapy

排除标准

  • Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab during the core study
  • Pregnancy, lactation.
  • Women of childbearing potential who do not use adequate contraception.

研究者

发起方
ovartis

相似试验